
-
无工作经验
-
招若干人
-
11-09 发布
职位描述
泰州迈博太科药业有限公司于2015年入驻泰州市中国医药城,注册资本2000万美元。公司主要从事单抗药物生产,投资总额2亿美元,拟建厂房面积3万余平方,建设符合GMP标准的国际先进的抗体药物制备体系,以期打造国内抗体药物生产高地。迈博太科药业由上海张江生物技术有限公司(抗体药物与靶向治疗国家重点实验室)抗体研发团队提供一站式平台服务,致力于实现一系列重量级国家创新抗体药物的产业化。现有品种:治疗结直肠癌的重组抗EGFR人鼠嵌合单克隆抗体,治疗银屑病的重组人LFA3-抗体融合蛋白等。 Taizhou Mabtech Pharmaceutical Co., Ltd. joined the China Medical City (CMC) in 2015 with registered capital of USD 20 million, expanding a national highland for monoclonal antibody medicine manufacturing by establishing internationally advanced antibody medicine manufacture system with adopted cGMP standards, with a total investment of USD 200 million. Supported by the one-stop platform for therapeutic mAb medicine development provided by ZJ-Bio R&D Team (State Key Laboratory of Antibody Medicine and Targeted Therapy), Taizhou Mabtech Pharmaceutics Co., Ltd is dedicated to industrialization of a series of “blockbuster” innovative antibody drugs. Existing varieties: recombinant anti-EGFR human/mouse-chimeric monoclonal antibody for the treatment of colorectal cancer, recombinant human LFA3-antibody fusion protein for the treatment of psoriasis , et al. 视 频 资 料 http://www.tz2100.com/news/dqxw/gx/2015/4/9/1428544031298.shtml
联系方式
泰州医药高新技术产业园
公司信息
泰州迈博太科药业有限公司于2015年入驻泰州市中国医药城,注册资本2000万美元。公司主要从事单抗药物生产,投资总额2亿美元,拟建厂房面积3万余平方,建设符合GMP标准的国际先进的抗体药物制备体系,以期打造国内抗体药物生产高地。迈博太科药业由上海张江生物技术有限公司(抗体药物与靶向治疗国家重点实验室)抗体研发团队提供一站式平台服务,致力于实现一系列重量级国家创新抗体药物的产业化。现有品种:治疗结直肠癌的重组抗EGFR人鼠嵌合单克隆抗体,治疗银屑病的重组人LFA3-抗体融合蛋白等。 Taizhou Mabtech Pharmaceutical Co., Ltd. joined the China Medical City (CMC) in 2015 with registered capital of USD 20 million, expanding a national highland for monoclonal antibody medicine manufacturing by establishing internationally advanced antibody medicine manufacture system with adopted cGMP standards, with a total investment of USD 200 million. Supported by the one-stop platform for therapeutic mAb medicine development provided by ZJ-Bio R&D Team (State Key Laboratory of Antibody Medicine and Targeted Therapy), Taizhou Mabtech Pharmaceutics Co., Ltd is dedicated to industrialization of a series of “blockbuster” innovative antibody drugs. Existing varieties: recombinant anti-EGFR human/mouse-chimeric monoclonal antibody for the treatment of colorectal cancer, recombinant human LFA3-antibody fusion protein for the treatment of psoriasis , et al. 视 频 资 料 http://www.tz2100.com/news/dqxw/gx/2015/4/9/1428544031298.shtml
泰州相关职位
-
山西OTC专员 4.5-6千/月
-
生产总监 1.5-2.5万/月
-
湖南OTC主管 4.5-6千/月
-
QA(体外诊断试剂) 3-4.5千/月
-
验证专员 3-4.5千/月
-
质量负责人 0.8-1.2万/月
-
注射针产品技术工程师(医疗器械) 6-8千/月
-
仓库管理员(化试对照品管理员)J11026 3-4.5千/月
-
采购主管 4-8千/月
-
质量经理 0.8-1万/月
-
物控经理(江苏泰州) 6-8千/月
-
研发总监/经理(江苏泰州) 1-1.5万/月
-
设备管理员 3-4.5千/月
-
质量管理QA 4.5-6千/月
-
市场推广专员J10468 6-8千/月